Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 323.79M P/E - EPS this Y 56.10% Ern Qtrly Grth -
Income -217.57M Forward P/E -1.85 EPS next Y 63.90% 50D Avg Chg -39.00%
Sales 100.39M PEG - EPS past 5Y - 200D Avg Chg -45.00%
Dividend N/A Price/Book 0.81 EPS next 5Y - 52W High Chg -66.00%
Recommedations 2.40 Quick Ratio 3.85 Shares Outstanding 51.31M 52W Low Chg 1.00%
Insider Own 2.50% ROA -22.17% Shares Float 49.61M Beta 1.85
Inst Own 98.51% ROE -76.91% Shares Shorted/Prior 6.81M/5.59M Price 6.45
Gross Margin 70.69% Profit Margin -216.73% Avg. Volume 855,224 Target Price 11.00
Oper. Margin -560.47% Earnings Date May 1 Volume 1,571,225 Change -7.06%
About 2seventy bio, Inc.

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

2seventy bio, Inc. News
04/05/24 U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
04/01/24 2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
03/20/24 2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
03/15/24 FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
03/07/24 Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term
03/06/24 When Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit?
03/05/24 2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
03/01/24 2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
02/05/24 2seventy bio to Participate in Upcoming Investor Conferences
02/05/24 Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
01/30/24 2seventy bio Announces New Strategic Path Forward
12/11/23 Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
12/11/23 2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
12/06/23 2seventy bio Reiterates Commitment to Maximizing Shareholder Value
11/20/23 Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
11/14/23 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
11/10/23 2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
09/12/23 2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
09/12/23 2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies
09/06/23 2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference
TSVT Chatroom

User Image scott52 Posted - 28 minutes ago

$TSVT I'll believe this sell off is over when NVDA is $665.

User Image TheWinningStock Posted - 6 hours ago

$IBRX <<<---well longs, $tsvt $gsk $crdl we are almost a the finish line, two more business days and the price should top to no less than $15, good luck, see ya in Vegas!..

User Image JerryMalone32 Posted - 17 hours ago

@Frank_Mondo @spderman @Fatpocketz Unfortunately, yes. And another million on $tsvt. Thank you Nick Leschly.

User Image ians Posted - 19 hours ago

$TSVT C’mon $BMY, Abecma is ripe for the taking. Total control of the manufacturing process can not only reduce cost & increase margins but also help patients receive their therapy sooner. Time to own the entire 3L+ r/r MM market. $15-20 BO 😉☘️💎

User Image Gerni130_MonopolyMan Posted - 21 hours ago

$TSVT i am out > change to $HOLO yesterday.

User Image scott52 Posted - 21 hours ago

$TSVT Back to $3.85.

User Image Myardiny_Toe Posted - 22 hours ago

$TSVT back to $1.50 boys and girls

User Image Quantumup Posted - 1 day ago

BMO Capital $LEGN Outperform/$90: "1Q24 Sales Missed Consensus by ~8%; We Don't see any Long-Term Impact" BMO expects the 2L approval2 sig'ly expand the addressable pop/demand +w/ mfg'g scaling will enable Carvykti sales2meet/beat '24 cons expys (~$1B): $ACLX $jnj $gild $tsvt bmy

User Image JerryMalone32 Posted - 2 days ago

@Fatpocketz @spderman I'm right there with fatpockets. Down over a million with $blue and over a million also with $tsvt ... Still holding because I believe $blue will do well with SCD, and because I believe $tsvt could get bought out by $bmy .... But nothing Obenshain & Co. do shocks me anymore. Not since that PRV fuck-up. They're the absolute worst. They make Leschly look competent.

User Image valueforme Posted - 2 days ago

$TSVT Understand the landscape. "While BCMA Car-T has produced better response rates than T-cell engagers in late-line multiple myeloma, bispecifics have advantages including the fact they can be used immediately and don’t require prior lymphodepletion" https://www.oncologypipeline.com/apexonco/tecvayli-threatens-eclipse-carvykti

User Image jayslow Posted - 2 days ago

$TSVT the lowest price of the year, I guess.

User Image jayslow Posted - 2 days ago

$TSVT ER 1st week of May?

User Image KY3000 Posted - 2 days ago

$TSVT different company now, they going to be close to a quarterly profit in Q1. Even without a BO, fundamentals that are coming are unheard of in biotech

User Image Peterson28 Posted - 3 days ago

$TSVT wow. It is really NOT cyclical at all. Just underperformed the market significantly only. Very smart.

User Image valueforme Posted - 3 days ago

$TSVT J&J reported Q1 2024 today Carvykti sales are almost flat 2 quarters in the row. Competition from T-Cell engagers and bispecifics is significant . Of course things will change as they are 2L+ now. BMS is reporting on Apr 25th Abecma's trajectory is way worse as you know. Q1 2024 will unlikely be good. Q2 2024 will be transitional and Q3-Q4 2024 will allow us to reason about 3L+ and sLVV impact . Don't forget that TSVT is only sharing profits and losses on US sales of Abecma

User Image TheWinningStock Posted - 4 days ago

$IBRX <<<-- Please consider listening to this podcast; it looks very promising for approval next week. $TSVT $CRDL $PFE https://www.youtube.com/watch?v=WtECko8gZIU

User Image JerryMalone32 Posted - 4 days ago

@stock_master84 So, first, $blue has never been found to be infringing by a court. There was a settlement between Girondi, MSK and $blue .... The RICO lawsuit filed by Girondi alleges that he was DUPED into settling, and he fantasizes that the $tsvt $blue spinoff was part of a master plan to rip him off. Girondi is a nutball.

User Image TheWinningStock Posted - 4 days ago

$TSVT <<--moderate buy, long hold...

User Image valueforme Posted - 5 days ago

$TSVT Abecma is indicated in Triple-class exposed (TCE) multiple myeloma, which occurs when a patient has received treatment with at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody. Carvykti is indicated for patients who have received a PI and an immunomodulatory agent, and are lenalidomide-refractory. So, Carvykti is going to compete with anti-CD38 (or bispecifics) for the 2nd line. Abecma is going to try to attract patients that failed anti-CD38 / bispecifics. I doubt there will be a lot of "take Abecma after the failed Carvykti" cases. Both are BCMA targeting

User Image KY3000 Posted - 6 days ago

$TSVT so how does this work? Legend does 2nd line, patient progresses to 3rd line, doc gives legend again? Or try TSVT?, than last line, we do a car-t again?

User Image valueforme Posted - 6 days ago

$TSVT SSR for Monday TSVT,"2sevety bio, Inc. Cm St",Q,4/12/2024 3:04:02 PM

User Image radham Posted - 6 days ago

$TSVT but what kinda fuckery is this??

User Image mcrotary Posted - 6 days ago

$TSVT still bullish.. markets will and always recover..

User Image radham Posted - 1 week ago

$TSVT how????!

User Image blueb22 Posted - 1 week ago

$TSVT - with this price suppression/manipulation and quite message board, I think (and believe) that BO could be announced on any fine Monday morning ... it could be next Monday ... it could be week after next ... it could be in a Month ... or in couple months ... but that will happen for sure. It could be BMS (most probably suiter), but it could be someone else, like Pfizer, or Gilead, or any other pharma (given it is lean company with 65 employees and only focus on Abecma). Hope it is BO like PRVB (by partner with 250% premium) and this high premium is fair for TSVT valuation at this stage with 3rd line approval, sLLV approval, and 1st line study ongoing etc). Good Luck! and Fingers Crossed!

User Image Myardiny_Toe Posted - 1 week ago

$TSVT

User Image KY3000 Posted - 1 week ago

$TSVT 70% margins, 120$ mill to break even, this is about to become a cash register

User Image Trending__Now Posted - 1 week ago

$TSVT One of the easiest plays in the stock market. 1) FDA approval 2) Indication expanding 3) Market Cap is almost = to cash on hand. 4) Yearly market sales potential of $500 million per year. 5) BMY is TSVTs partner in trials and produces the therapy. 6) Buyout target for BMY. Good grief...the cash is sitting in the company for the buyout.

User Image Doorkey Posted - 1 week ago

$TSVT Now at 91%...after scalping VERU

User Image mcrotary Posted - 1 week ago

$TSVT from 1 hour time frame upwards looking beautiful again..

Analyst Ratings
Citigroup Buy Apr 8, 24
Wedbush Neutral Mar 18, 24
Leerink Partners Outperform Jan 31, 24
TD Cowen Market Perform Jan 31, 24
Wedbush Neutral Nov 20, 23
Leerink Partners Market Perform Oct 30, 23
Citigroup Buy Oct 12, 23
Guggenheim Neutral Sep 13, 23
Goldman Sachs Neutral Sep 13, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Leschly Nick President and CEO President and CEO Aug 22 Sell 5.4865 9,312 51,090 1,159,342 08/24/23
Gregory Philip D Chief Scientific Off.. Chief Scientific Officer Aug 22 Sell 5.4865 6,159 33,791 257,250 08/24/23
Baird William D III Chief Financial Offi.. Chief Financial Officer Aug 22 Sell 5.4865 7,031 38,576 196,366 08/24/23
Kynam Global Healthcare Master... 10% Owner 10% Owner Aug 10 Buy 5.91 601,828 3,556,803 5,142,111 08/16/23
Kynam Capital Management, LP 10% Owner 10% Owner Aug 10 Buy 5.91 601,828 3,556,803 5,142,111 08/14/23
Baird William D III Chief Financial Offi.. Chief Financial Officer Feb 13 Sell 12.86 637 8,192 210,303 02/15/23
Gregory Philip D Chief Scientific Off.. Chief Scientific Officer Jan 11 Sell 10.6281 1,076 11,436 99,518 01/18/23
Heffron Nicola Chief Operating Offi.. Chief Operating Officer Jan 11 Sell 10.6281 128 1,360 89,242 01/18/23
Leschly Nick President and CEO President and CEO Jan 11 Sell 10.6281 2,026 21,533 534,393 01/18/23
Baird William D III Chief Financial Offi.. Chief Financial Officer Jan 11 Sell 10.6281 1,077 11,446 78,797 01/18/23
Heffron Nicola Chief Operating Offi.. Chief Operating Officer Dec 05 Sell 15.4328 272 4,198 89,954 12/06/22
Baird William D III Chief Financial Offi.. Chief Financial Officer Aug 05 Sell 16.2325 4,152 67,397 83,096 08/08/22
Gregory Philip D Chief Scientific Off.. Chief Scientific Officer Aug 05 Sell 16.2325 2,407 39,072 104,388 08/08/22
Leschly Nick President and CEO President and CEO Aug 05 Sell 16.2325 5,499 89,263 545,985 08/08/22
Leschly Nick President and CEO President and CEO Mar 17 Buy 12.20 368,857 4,500,055 556,888 03/22/22
Baird William D III Chief Financial Offi.. Chief Financial Officer Feb 17 Sell 14.78 427 6,311 57,578 02/22/22
Baird William D III Chief Financial Offi.. Chief Financial Officer Jan 07 Sell 23.9078 896 21,421 58,005 01/11/22
Gregory Philip D Chief Scientific Off.. Chief Scientific Officer Jan 07 Sell 23.9078 1,452 34,714 61,660 01/11/22
Leschly Nick President and CEO President and CEO Jan 07 Sell 23.9078 3,270 78,179 188,031 01/11/22